R&D channel feed – Endpoints News

R&D channel feed

In at least one life-sci hub, gender and diversity initiatives haven’t made a dent

6 years ago

One less rival for Immunovant, as Alexion abandons FcRn inhibitor

6 years ago

Biogen touts new evidence from the gene therapy company it wagered $800M on

6 years ago

First US Covid-19 trials set to get underway in Nebraska and Washington, backed by NIH

6 years ago

NIH-partnered Moderna ships off its PhI-ready coronavirus vaccine candidate to a sea of uncertainty

6 years ago

NGM Bio takes leap forward in crowded NASH field

6 years ago

Novartis gets a boost in blockbuster multiple sclerosis race with Roche

6 years ago

A space odyssey for new antibiotics: MIT's machine learning approach

6 years ago

Gilead loses two more patent challenges on HIV pill, setting up courtroom fight in Delaware

6 years ago

DBV's peanut prevention patch approaches key stage of approval process

6 years ago

Merck loses its chief digital officer, spotlighting talent hunt for the hottest title in Big Pharma

6 years ago

Armed with a batch of positive biomarker data, a rare disease player reaps $88M for the next big push in the clinic

6 years ago

For two decades, a new vaccine technology has been slowly approaching prime time. Now, can it stop a pandemic?

6 years ago

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

6 years ago

Bristol-Myers shrugs off another Opdivo combo flop as $1.74B deal goes pfffft

6 years ago

Astellas follows up $3B gene therapy buyout with $109M plan to accelerate a manufacturing boom

6 years ago

He built a MERS treatment in 6 months and then the best Ebola drug. Now Christos Kyratsous turns his sights on Covid-19

6 years ago

FDA goes on high alert as coronavirus raises threat to drug manufacturing and clinical trials grind to a halt

6 years ago

Warren Buffett gets a double take as the investment powerhouse settles on its first biotech investment

6 years ago

If you were a cancer patient, where would you rather be — the United States or Europe?

6 years ago

AstraZeneca's Chinese investment bank partner raises $229M for its own new fund — and it's all about the coronavirus

6 years ago

Coronavirus outbreak clouds AstraZeneca's Q4 results and 2020 outlook

6 years ago

Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine

6 years ago

The White House review of drug prices: Don't hate the player — hate the game

6 years ago

First page Previous page 210 211 212213214 215 216 Next page Last page